The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
September 21, 2022 — As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of…
Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci
August 23, 2022 — Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.
Ten Principles for Access to Multi-disease Molecular Diagnostics: A Global Call to Action
August 23, 2022 — Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.
Treatment Action Group Adds Three New Board Members
August 23, 2022 — As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
August 1, 2022 — We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
August 1, 2022 — Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
1 / 4 / 6 x 24 Campaign Launched to Rally Energy, Political Will, Funding Needed to Fight Tuberculosis
July 31, 2022 — Against the backdrop of the COVID-19 pandemic and other concurrent global health, economic, social, and political crises, the 1 / 4 / 6 x 24 Campaign, launched during the AIDS conference in Montreal, seeks to improve TB treatment and prevention worldwide based on the latest medical innovations and to reignite…
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
July 1, 2022 — A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.
Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement
June 23, 2022 — In response to this morning’s announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group’s Executive Director, Mark Harrington, and TAG HIV Project Director…
Treatment Action Group Mourns Urvashi Vaid, Celebrates Her Life and Legacy
May 17, 2022 — Treatment Action Group (TAG) today mourns the premature loss of transformative LGBTQ and AIDS activist Urvashi Vaid, formerly executive director of the National Gay and Lesbian Task Force (now the National LGBTQ Task Force) at the height of the U.S. AIDS crisis in the late 1980s and early 1990s, and…